Intelligent anti-aging skin care based on independent research     
Lose wrinkles, keep your bank account!     
 
Skin Care 101
Skin Care Basics
Skin Protection
Skin Biology
Biology of Aging
Ingredient Guide
Skin & Nutrition
Skin Conditions
 
Anti-Aging Treatments
Topical Actives
Wrinkle Fillers
Noninvasive
Invasive
 
Skin Care Smarts
Smart Choices
Best Practices
Find Good Skin Doc
Quick Tips
Freebie Finder
 
Reviews & Research
Product Reviews
Provider Reviews
Skin Care Research
Clinical Trials
 
How-To Infopacks
Skin Rejuvenation
DIY Skin Care
Skin & Nutrition
Eye Skin Care
Longevity In a Pill
 
Community & Misc
Forums
Polls & Surveys
News and Updates
Search

-- advertisements --
   
You are here: Clinical Trials >

Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne

Information provided by Pfizer
Information obtained from ClinicalTrials.gov on June 16, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) treated: Acne Vulgaris

Intervention: Azithromycin microspheres (Drug); minocycline-placebo capsules (Drug); Azithromycin microspheres-placebo (Drug); Minocycline capsules, (Drug)

Phase: Phase 3

Enrollment status: Recruiting

Sponsor: Pfizer

Principal investigator(s) or official(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Overall contact:
Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Summary

The primary objective is to evaluate the clinical efficacy of azithromycin microspheres treatment in outpatients with moderate to severe inflammatory acne compared with first line treatment minocycline after 8 weeks of therapy

Clinical Details

Official title: A Phase III, Multicenter, Randomized, Double Blind-Double Dummy Study, To Evaluate Efficacy And Safety Of Treatment With Azithromycin, Microspheres, Oral Powder For Suspension, 2 G, In One Administration A Week, For 8 Weeks, Compared With Treatment With Minocycline Capsules, 100 Mg Die For 8 Weeks, In Outpatients With Moderate To Severe Inflammatory Acne.

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Efficacy Study

Primary outcome: Compare the means of GAGS (objective grading of acne) scores reduction between baseline and visit 3 (end of treatment) in the two treatment groups (Time Frame: baseline and visit 3 (end of treatment))

Secondary outcome:
After having clustered patients by the rate of severity, according to the GAGS score (see below), the size of each cluster will be compared between the two groups of treatment, at the end of treatment. (Time Frame: visit 2 EOT after 8 weeks of treatment)

Internal comparison of pre-post therapy GAGS score, in both group of treatment. (Time Frame: visit 2 EOT after 8 weeks of treatment)

In both groups, the different clusters of patients (by the rate of severity, and graded according the GAGS score) will be assessed, as internal comparison, in a pre-post therapy evaluation, defining: (Time Frame: visit 2 EOT after 8 weeks of treatment)

1. Best improvement: reduction > 75% of score between pre-post evaluation. 2. Good improvement: reduction >50 - 75% of score between pre-post evaluation. 3. Moderate improvement: reduction >25 - 50% of score between pre-post (Time Frame: visit 2 EOT after 8 weeks of treatment)

evaluation 4. Light improvement: reduction <25% of score between pre-post evaluation. (Time Frame: visit 2 EOT after 8 weeks of treatment)

Eligibility

Minimum eligible age: 16 Years. Eligible gender(s): Both.

Criteria:

Inclusion Criteria:

- male and female, older than 16 years, with diagnosis of acne papulo-pustular, moderate

(19-30 GAGS score) to severe (31-33 GAGS score)

Exclusion Criteria:

- pregnancy, gastrointestinal and endocrinological disease, specific systemic disease,

oral contraceptives, isotretinoin, topic drugs for acne (except detergent allowed)

Locations and Contact Information

Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Pfizer Investigational Site, Napoli 80131, Italy; Active, not recruiting

Pfizer Investigational Site, Ferrara 44100, Italy; Active, not recruiting

Pfizer Investigational Site, Bologna 40121, Italy; Completed

Pfizer Investigational Site, Milano 20100, Italy; Active, not recruiting

Pfizer Investigational Site, Trieste 34100, Italy; Recruiting

Pfizer Investigational Site, Messina 98100, Italy; Recruiting

Pfizer Investigational Site, Pordenone 33170, Italy; Recruiting

Pfizer Investigational Site, Lucca 55100, Italy; Active, not recruiting

Pfizer Investigational Site, Siena 53100, Italy; Active, not recruiting

Pfizer Investigational Site, Pisa 56126, Italy; Active, not recruiting

Pfizer Investigational Site, Roma 00161, Italy; Recruiting

Pfizer Investigational Site, Roma 00167, Italy; Recruiting

Pfizer Investigational Site, Terni 05100, Italy; Active, not recruiting

Pfizer Investigational Site, Genova 16132, Italy; Active, not recruiting

Pfizer Investigational Site, Catania 95124, Italy; Recruiting

Pfizer Investigational Site, Catanzaro 88100, Italy; Completed

Pfizer Investigational Site, Germona del Friuli, Udine 33013, Italy; Recruiting

Additional Information

To obtain contact information for a study center near you, click here.

Start date: December 2006
Last updated: June 6, 2008


Google
 
Web SmartSkinCare.com

Home | About Us | Contact Us | Ask a Question | Resources

Copyright © 1999-2008 by Dr. G. Todorov / SmartSkinCare.com
Site Disclaimer | Copyright Certification

   
-- advertisements --